Amino acid carbamates as prodrugs of resveratrol

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Mattarei, Andrea ^a   Azzolini, Michele ^a,b,c   La Spina, Martina ^a   Zoratti, Mario ^a,b   Paradisi, Cristina ^a   Biasutto, Lucia ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b CNR   (Italy)

^c NÓOS Srl   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CARBAMIC ACID DERIVATIVE; PRODRUG; RESVERATROL; STILBENE DERIVATIVE;

ANIMAL; CHEMISTRY; DRUG DESIGN; MALE; METABOLIC CLEARANCE RATE; ORAL DRUG ADMINISTRATION; RAT; SYNTHESIS; WISTAR RAT;

ADMINISTRATION, ORAL; AMINO ACIDS; ANIMALS; CARBAMATES; DRUG DESIGN; MALE; METABOLIC CLEARANCE RATE; PRODRUGS; RATS; RATS, WISTAR; STILBENES;

EID: 84944382558     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15216     Document Type: Article

References (61)

1. Jeandet, P. et al. Biosynthesis, metabolism, molecular engineering, and biological functions of stilbene phytoalexins in plants. Biofactors 36, 331-341, doi: 10.1002/biof.108 (2010).
2. Agarwal, B. & Baur, J. A. Resveratrol and life extension. Ann N Y Acad Sci 1215, 138-143, doi: 10.1111/j.1749-6632.2010.05850.x (2011).
3. Csiszar, A. Anti-inflammatory effects of resveratrol: possible role in prevention of age-related cardiovascular disease. Ann N Y Acad Sci 1215, 117-122, doi: 10.1111/j.1749-6632.2010.05848.x (2011).
4. Kroon, P. A., Iyer, A., Chunduri, P., Chan, V. & Brown, L. The cardiovascular nutrapharmacology of resveratrol: pharmacokinetics, molecular mechanisms and therapeutic potential. Curr Med Chem 17, 2442-2455, doi: 10.2174/092986710791556032 (2010).
5. Khurana, S., Venkataraman, K., Hollingsworth, A., Piche, M. & Tai, T. C. Polyphenols: benefits to the cardiovascular system in health and in aging. Nutrients 5, 3779-3827, doi: 10.3390/nu5103779 (2013).
6. Raederstorff, D., Kunz, I. & Schwager, J. Resveratrol, from experimental data to nutritional evidence: the emergence of a new food ingredient. Ann N Y Acad Sci 1290, 136-141, doi: 10.1111/nyas.12147 (2013).
7. Szkudelski, T. & Szkudelska, K. Anti-diabetic effects of resveratrol. Ann N Y Acad Sci 1215, 34-39, doi: 10.1111/j.1749-6632.2010.05844.x (2011).
8. Liu, K., Zhou, R., Wang, B. & Mi, M. T. Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr 99, 1510-1519, doi: 10.3945/ajcn.113.082024 (2014).
9. Baile, C. A. et al. Effect of resveratrol on fat mobilization. Ann N Y Acad Sci 1215, 40-47, doi: 10.1111/j.1749-6632.2010.05845.x (2011).
10. Wang, S. et al. Novel insights of dietary polyphenols and obesity. J Nutr Biochem 25, 1-18, doi: 10.1016/j.jnutbio.2013.09.001 (2014).
11. Andrade, J. M. et al. Resveratrol increases brown adipose tissue thermogenesis markers by increasing SIRT1 and energy expenditure and decreasing fat accumulation in adipose tissue of mice fed a standard diet. Eur J Nutr, doi: 10.1007/s00394-014- 0655-6 (2014).
12. Andrade, J. M. et al. Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation. Nutrition 30, 915-919, doi: 10.1016/j.nut.2013.11.016 (2014).
13. Biasutto, L., Szabo, I. & Zoratti, M. Mitochondrial effects of plant-made compounds. Antioxid Redox Signal 15, 3039-3059, doi: 10.1089/ars.2011.4021 (2011).
14. Park, S. J. et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148, 421-433, doi: 10.1016/j.cell.2012.01.017 (2012).
15. Foti Cuzzola, V., Ciurleo, R., Giacoppo, S., Marino, S. & Bramanti, P. Role of resveratrol and its analogues in the treatment of neurodegenerative diseases: focus on recent discoveries. CNS Neurol Disord Drug Targets 10, 849-862, doi: 10.2174/187152711798072310 (2011).
16. Quincozes-Santos, A. & Gottfried, C. Resveratrol modulates astroglial functions: neuroprotective hypothesis. Ann N Y Acad Sci 1215, 72-78, doi: 10.1111/j.1749-6632.2010.05857.x (2011).
17. Aggarwal, B. B. et al. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 24, 2783-2840 (2004).
18. Vanden Berghe, W. Epigenetic impact of dietary polyphenols in cancer chemoprevention: lifelong remodeling of our epigenomes. Pharmacol Res 65, 565-576, doi: 10.1016/j.phrs.2012.03.007 (2012).
19. Kaminski, B. M., Steinhilber, D., Stein, J. M. & Ulrich, S. Phytochemicals resveratrol and sulforaphane as potential agents for enhancing the anti-tumor activities of conventional cancer therapies. Curr Pharm Biotechnol 13, 137-146, doi: 10.2174/138920112798868746 (2012).
20. Gupta, S. C., Kannappan, R., Reuter, S., Kim, J. H. & Aggarwal, B. B. Chemosensitization of tumors by resveratrol. Ann N Y Acad Sci 1215, 150-160, doi: 10.1111/j.1749-6632.2010.05852.x (2011).
21. Cottart, C. H., Nivet-Antoine, V. & Beaudeux, J. L. Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans. Mol Nutr Food Res 58, 7-21, doi: 10.1002/mnfr.201200589 (2014).
22. Subramanian, L. et al. Resveratrol: challenges in translation to the clinic-a critical discussion. Clin Cancer Res 16, 5942-5948, doi: 10.1158/1078-0432.ccr-10-1486 (2010).
23. Walle, T. Bioavailability of resveratrol. Ann N Y Acad Sci 1215, 9-15, doi: 10.1111/j.1749-6632.2010.05842.x (2011).
24. Yu, C. et al. Human, rat, and mouse metabolism of resveratrol. Pharm Res 19, 1907-1914, doi: 10.1023/A:1021414129280 (2002).
25. Bresciani, L. et al. Bioaccumulation of resveratrol metabolites in myocardial tissue is dose-time dependent and related to cardiac hemodynamics in diabetic rats. Nutr Metab Cardiovasc Dis 24, 408-415, doi: 10.1016/j.numecd.2013.09.008 (2014).
26. Walker, J. et al. Resveratrol and its metabolites inhibit pro-inflammatory effects of lipopolysaccharides in U-937 macrophages in plasma-representative concentrations. Food Funct 5, 74-84, doi: 10.1039/c3fo60236b (2014).
27. Eseberri, I., Lasa, A., Churruca, I. & Portillo, M. P. Resveratrol metabolites modify adipokine expression and secretion in 3T3-L1 pre-adipocytes and mature adipocytes. PLoS One 8, e63918, doi: 10.1371/journal.pone.0063918 (2013).
28. Lasa, A., Churruca, I., Eseberri, I., Andres-Lacueva, C. & Portillo, M. P. Delipidating effect of resveratrol metabolites in 3T3-L1 adipocytes. Mol Nutr Food Res 56, 1559-1568, doi: 10.1002/mnfr.201100772 (2012).
29. Kenealey, J. D. et al. Resveratrol metabolites do not elicit early pro-apoptotic mechanisms in neuroblastoma cells. J Agric Food Chem 59, 4979-4986, doi: 10.1021/jf104901g (2011).
30. Lu, D. L. et al. Influence of glucuronidation and reduction modifications of resveratrol on its biological activities. Chembiochem 14, 1094-1104, doi: 10.1002/cbic.201300080 (2013).
31. Calamini, B. et al. Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem J 429, 273-282, doi: 10.1042/ bj20091857 (2010).
32. Hoshino, J. et al. Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem 53, 5033-5043, doi: 10.1021/jm100274c (2010).
33. Herath, W., Khan, S. I. & Khan, I. A. Microbial metabolism. Part 14. Isolation and bioactivity evaluation of microbial metabolites of resveratrol. Nat Prod Res 27, 1437-1444, doi: 10.1080/14786419.2012.722089 (2013).
34. Ruotolo, R. et al. Anti-estrogenic activity of a human resveratrol metabolite. Nutr Metab Cardiovasc Dis 23, 1086-1092, doi: 10.1016/j.numecd.2013.01.002 (2013).
35. Patel, K. R. et al. Sulfate metabolites provide an intracellular pool for resveratrol generation and induce autophagy with senescence. Sci Transl Med 5, 205ra133, doi: 10.1126/scitranslmed.3005870 (2013).
36. Andreadi, C., Britton, R. G., Patel, K. R. & Brown, K. Resveratrol-sulfates provide an intracellular reservoir for generation of parent resveratrol, which induces autophagy in cancer cells. Autophagy 10, 524-525, doi: 10.4161/auto.27593 (2014).
37. Ghosh, A. K. & Brindisi, M. Organic Carbamates in Drug Design and Medicinal Chemistry. J Med Chem, doi: 10.1021/jm501371s (2015).
38. Hansen, J., Mrk, N. & Bundgaard, H. Phenyl carbamates of amino acids as prodrug forms for protecting phenols against firstpass metabolism. Int J Pharm 81, 253-261, doi: 10.1016/0378-5173(92)90017-V (1992).
39. Biasutto, L. & Zoratti, M. Prodrugs of quercetin and resveratrol: a strategy under development. Curr Drug Metab 15, 77-95, doi: 10.2174/1389200214666131211160005 (2014).
40. Ferriz, J. M. & Vinsova, J. Prodrug design of phenolic drugs. Curr Pharm Des 16, 2033-2052, doi: 10.2174/138161210791293042 (2010).
41. Dhareshwar, S. & Stella, V. In Prodrugs Vol. V Biotechnology: Pharmaceutical Aspects eds Valentino J Stella et al.) Ch. 21, 731-799 (Springer New York, 2007).
42. Mulholland, P. J. et al. Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin. Ann Oncol 12, 245-248, doi: 10.1023/A:1008372017097 (2001).
43. Kim, M. K., Park, K. S., Yeo, W. S., Choo, H. & Chong, Y. In vitro solubility, stability and permeability of novel quercetin-amino acid conjugates. Bioorg Med Chem 17, 1164-1171, doi: 10.1016/j.bmc.2008.12.043 (2009).
44. Mattarei, A. et al. New water-soluble carbamate ester derivatives of resveratrol. Molecules (Basel, Switzerland) 19, 15900-15917, doi: 10.3390/molecules191015900 (2014).
45. Vig, B. S., Huttunen, K. M., Laine, K. & Rautio, J. Amino acids as promoieties in prodrug design and development. Adv Drug Deliver Rev 65, 1370-1385, doi:10.1016/j.addr.2012.10.001 (2013).
46. Broer, S. Amino acid transport across mammalian intestinal and renal epithelia. Physiol Rev 88, 249-286, doi: 10.1152/ physrev.00018.2006 (2008).
47. Brandsch, M. Drug transport via the intestinal peptide transporter PepT1. Curr Opin Pharmacol 13, 881-887, doi: 10.1016/j. coph.2013.08.004 (2013).
48. Estudante, M., Morais, J. G., Soveral, G. & Benet, L. Z. Intestinal drug transporters: an overview. Adv Drug Deliver Rev 65, 1340-1356, doi: 10.1016/j.addr.2012.09.042 (2013).
49. Tamai, I. Oral drug delivery utilizing intestinal OATP transporters. Adv Drug Deliver Rev 64, 508-514, doi: 10.1016/j. addr.2011.07.007 (2012).
50. del Amo, E. M., Urtti, A. & Yliperttula, M. Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. Eur J Pharm Sci 35, 161-174, doi: 10.1016/j.ejps.2008.06.015 (2008).
51. Gynther, M. et al. Large neutral amino acid transporter enables brain drug delivery via prodrugs. J Med Chem 51, 932-936, doi: 10.1021/jm701175d (2008).
52. Peura, L. et al. Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery. Mol Pharm 8, 1857-1866, doi: 10.1021/mp2001878 (2011).
53. Peura, L. et al. Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine. Pharm Res 30, 2523-2537, doi: 10.1007/s11095-012-0966-3 (2013).
54. Wu, X., Cheng, L., Xiang, D. & Wei, Y. Syntheses of Carbamate Derivatives of Quercetin by Reaction with Amino Acid Ester Isocyanates. Lett Org Chem 2, 535-538, doi: 10.2174/1570178054640796 (2005).
55. Kozerski, G. E., Gallavan, R. H. & Ziemelis, M. J. Investigation of trialkoxysilane hydrolysis kinetics using liquid chromatography with inductively coupled plasma atomic emission spectrometric detection and non-linear regression modeling. Anal Chim Acta 489, 103-114, doi: 10.1016/S0003-2670(03)00710-4 (2003).
56. Adams, P. & Baron, F. A. Esters of Carbamic Acid. Chem Rev 65, 567-602, doi: 10.1021/cr60237a002 (1965).
57. Azzolini, M. et al. Pharmacokinetics and tissue distribution of pterostilbene in the rat. Mol Nutr Food Res 58, 2122-2132, doi: 10.1002/mnfr.201400244 (2014).
58. Biasutto, L., Marotta, E., Garbisa, S., Zoratti, M. & Paradisi, C. Determination of quercetin and resveratrol in whole blood-implications for bioavailability studies. Molecules (Basel, Switzerland) 15, 6570-6579, doi: 10.3390/ molecules15096570 (2010).
59. Biasutto, L. et al. Soluble polyphenols: synthesis and bioavailability of 3,4?,5-tri(alpha-D-glucose-3-O-succinyl) resveratrol. Bioorg Med Chem Lett 19, 6721-6724, doi: 10.1016/j.bmcl.2009.09.114 (2009).
60. Mattarei, A. et al. New derivatives of resveratrol. (2014). European Patent Application EP2774915. Application Number EP20140157948. Filing date 03/05/2014. Publication Date 09/10/2014.
61. Mattarei, A. et al. Acetal derivatives as prodrugs of resveratrol. Mol Pharm 10, 2781-2792, doi: 10.1021/mp400226p (2013).